Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Epsilon Reports Plan to Repurchase Shares Pursuant to a Normal Course Issuer Bid
Epsilon Energy Ltd.December 28, 2020 GMT
HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that the Board of Directors has authorized the repurchase of up to 1,193,000 of the outstanding common shares, representing 5% of the outstanding common shares of Epsilon, pursuant to a normal course issuer bid, during the one-year period commencing on January 1st, 2021. The program will end on December 31st, 2021 unless the maximum amount of common shares is purchased before then or Epsilon provides earlier notice of termination.
Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women s Health
wboc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wboc.com Daily Mail and Mail on Sunday newspapers.
U S Gold Corp durchteuft im Zuge von Bohrungen in seinem zweiten metallurgischen Bohrloch im Goldprojekt CK in Wyoming einen durchgehend mineralisierten Abschnitt mit 1,003 g/t Goldäquivalent auf 176,8 Meter
mittelstandcafe.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mittelstandcafe.de Daily Mail and Mail on Sunday newspapers.
Farallon requests Toshiba Corporation Convene an EGM to Explain and Seek Shareholder Approval Regarding Significant Changes to the Toshiba Next Plan Relating to a New One Trillion Yen Growth Investing Strategy Copyright 2021 PR Newswire. All Rights Reserved
2020-12-24
SAN FRANCISCO, Dec. 25, 2020 /PRNewswire/ Today, an affiliate of Farallon Capital Management, L.L.C. ( Farallon ) requested Toshiba Corporation ( Toshiba or the Company )(6502.T) convene an extraordinary general meeting of shareholders ( EGM ) to seek shareholder approval regarding significant changes to the Toshiba Next Plan ( TNP ) relating to a new one trillion yen growth investing plan.
Farallon has continued constructive discussions with Toshiba as a major shareholder since 2017, including recommending the appointment of Mr. Raymond Zage, who previously served as CEO and Managing Director of Farallon Capital Asia, to the Toshiba Board of Directors. Mr. Zage was appointed as a director of Toshib
Press release content from Business Wire. The AP news staff was not involved in its creation.
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
December 23, 2020 GMT
IRVINE, Calif. & BASEL, Switzerland (BUSINESS WIRE) Dec 23, 2020
Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. This approval marks the first new oral branded OAB medication approved by the FDA since 2012, and it is the first product approval for Urovant Sciences.